Drug Profile
CCX 140
Alternative Names: CCX-140B; CCX140Latest Information Update: 16 Nov 2018
Price :
$50
*
At a glance
- Originator ChemoCentryx
- Developer ChemoCentryx; Vifor
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic nephropathies; Focal segmental glomerulosclerosis
- Research Kidney disorders
- No development reported Type 2 diabetes mellitus
- Discontinued Multiple sclerosis; Vascular restenosis